Services
Trademarks
Protect your brand today
Register your Trademark
Post Filing Services
Trademark Protection
Patents
File a patent today
Start a Patent Application
Copyrights
Safeguard your creative ideas
Start a Copyright Application
Business
Incorporate your business today
Start a Business
Legal Forms for Business
Resources
Guest
SEARCHED
on 01 Nov 2023
Last Applicant/ Owned by
Camurus AB
Ideon Science ParkSE-223 70 Lund
SE
Serial Number
2199278 filed on 27th Apr 2022
Correspondent Address
745 Thurlow Street, Suite 2400Vancouver
BRITISH COLUMBIA
CA
V6E0C5
OCZYESA
Trademark usage description
pharmaceutical preparations for injection for the treatment of endocrine diseases and disorders; pharmaceutical preparations for injection for the tre Read MoreClassification Information
Class [005]
Pharmaceutical preparations for injection for the treatment of endocrine diseases and disorders; pharmaceutical preparations for injection for the treatment of tumours; pharmaceutical preparations for injection for the treatment of carcinoid tumours; pharmaceutical preparations for injection comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for injection for the treatment of neuroendocrine tumours; pharmaceutical preparations for injection for the treatment of gastro-enteropancreatic neuroendocrine tumours; pharmaceutical preparations for injection for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for injection for gastrointestinal bleeding disorders; pharmaceutical preparations for injection for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for injection for the treatment of esophageal bleeding; pharmaceutical preparations for injection for metabolic disorders; pharmaceutical preparations for injection for the treatment of acromegaly; pharmaceutical preparations for injection for the treatment of polycystic liver disease; pharmaceutical preparations for injection for the treatment of respiratory diseases or syndrome; pharmaceutical preparations for injection for the treatment of respiratory distress syndrome; pharmaceutical preparations for injection for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for injection for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations for injection intended to block growth hormone; Pharmaceutical preparations for subcutaneous injection for the treatment of endocrine diseases and disorders; pharmaceutical preparations for subcutaneous injection for the treatment of tumours; pharmaceutical preparations for subcutaneous injection for the treatment of carcinoid tumours; pharmaceutical preparations for subcutaneous injection comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for subcutaneous injection for the treatment of neuroendocrine tumours; pharmaceutical preparations for subcutaneous injection for the treatment of gastro-enteropancreatic neuroendocrine tumours; pharmaceutical preparations for subcutaneous injection for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for subcutaneous injection for gastrointestinal bleeding disorders; pharmaceutical preparations for subcutaneous injection for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for subcutaneous injection for the treatment of esophageal bleeding; pharmaceutical preparations for subcutaneous injection for metabolic disorders; pharmaceutical preparations for subcutaneous injection for the treatment of acromegaly; pharmaceutical preparations for subcutaneous injection for the treatment of polycystic liver disease; pharmaceutical preparations for subcutaneous injection for the treatment of respiratory diseases or syndrome; pharmaceutical preparations for subcutaneous injection for the treatment of respiratory distress syndrome; pharmaceutical preparations for subcutaneous injection for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for subcutaneous injection for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations for subcutaneous injection intended to block growth hormone; pharmaceutical preparations for the treatment of endocrine diseases and disorders; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for the treatment of carcinoid tumours; pharmaceutical preparations comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for the treatment of neuroendocrine tumours; pharmaceutical preparations for the treatment of gastro-enteropancreatic neuroendocrine tumours; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for gastrointestinal bleeding disorders; pharmaceutical preparations for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for the treatment of esophageal bleeding; pharmaceutical preparations for metabolic disorders; pharmaceutical preparations for the treatment of acromegaly; pharmaceutical preparations for the treatment of polycystic liver disease; pharmaceutical preparations for the treatment of respiratory diseases or syndrome; pharmaceutical preparations for the treatment of respiratory distress syndrome; pharmaceutical preparations for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations intended to block growth hormone
Classification kind code
11
Class [010]
Autoinjectors for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; autoinjectors for administration of pharmaceuticals for the treatment of tumours; autoinjectors for administration of pharmaceuticals for the treatment of carcinoid tumours; autoinjectors for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; autoinjectors for administration of pharmaceuticals for the treatment of neuroendocrine tumours; autoinjectors for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; autoinjectors for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; autoinjectors for administration of pharmaceuticals for gastrointestinal bleeding disorders; autoinjectors for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; autoinjectors for administration of pharmaceuticals for the treatment of esophageal bleeding; autoinjectors for administration of pharmaceuticals for metabolic disorders; autoinjectors for administration of pharmaceuticals for the treatment of acromegaly; autoinjectors for administration of pharmaceuticals for the treatment of polycystic liver disease; autoinjectors for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; autoinjectors for administration of pharmaceuticals for the treatment of respiratory distress syndrome; autoinjectors for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; autoinjectors for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; autoinjectors for administration of pharmaceuticals intended to block growth hormone; syringes for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; syringes for administration of pharmaceuticals for the treatment of tumours; syringes for administration of pharmaceuticals for the treatment of carcinoid tumours; syringes for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; syringes for administration of pharmaceuticals for the treatment of neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; syringes for administration of pharmaceuticals for gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of esophageal bleeding; syringes for administration of pharmaceuticals for metabolic disorders; syringes for administration of pharmaceuticals for the treatment of acromegaly; syringes for administration of pharmaceuticals for the treatment of polycystic liver disease; syringes for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; syringes for administration of pharmaceuticals for the treatment of respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; syringes for administration of pharmaceuticals intended to block growth hormone; pens for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; pens for administration of pharmaceuticals for the treatment of tumours; pens for administration of pharmaceuticals for the treatment of carcinoid tumours; pens for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; pens for administration of pharmaceuticals for the treatment of neuroendocrine tumours; pens for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; pens for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; pens for administration of pharmaceuticals for gastrointestinal bleeding disorders; pens for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; pens for administration of pharmaceuticals for the treatment of esophageal bleeding; pens for administration of pharmaceuticals for metabolic disorders; pens for administration of pharmaceuticals for the treatment of acromegaly; pens for administration of pharmaceuticals for the treatment of polycystic liver disease; pens for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; pens for administration of pharmaceuticals for the treatment of respiratory distress syndrome; pens for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; pens for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; pens for administration of pharmaceuticals intended to block growth hormone; devices for subcutaneous administration of pharmaceuticals; syringes for subcutaneous administration of pharmaceuticals; syringes for parenteral administration of pharmaceuticals; syringes for injection of pharmaceutical depots; syringes for subcutaneous injection of pharmaceutical depot; syringes for parenteral injection of pharmaceutical depot; syringes for injection of injection fluids; syringes for injection of injection depot; syringes for injections; syringes for medical uses; pens for subcutaneous administration of pharmaceuticals; pens for parenteral administration of pharmaceuticals; pens for injection of pharmaceutical depots; pens for subcutaneous injection of pharmaceutical depot; pens for parenteral injection of pharmaceutical depot; pens for injection of injection fluids; pens for injection of injection depot; pens for injections; pens for medical uses
Classification kind code
11
Mark Details
Serial Number
2199278
Mark Type
Trademark
Legal History
| Action Taken | Status |
|---|---|
| Submitted for opposition 48 on 20th Feb 2024 | Agent Changed |
| Submitted for opposition 22 on 01st Nov 2023 | Search Recorded |
| Submitted for opposition 20 on 01st Nov 2023 | Examiner's First Report |
| Submitted for opposition 223 on 01st Nov 2023 | Total Provisional Refusal |
| Submitted for opposition 256 on 22nd May 2023 | Notification of Possible Opposition Sent |
| Submitted for opposition 257 on 21st Jul 2022 | Designation Notification - Madrid Protocol |
| Submitted for opposition 31 on 20th Jul 2022 | Formalized |
| Submitted for opposition 1 on 20th Jul 2022 | Created |
| Submitted for opposition 228 on 27th Apr 2022 | International Registration |
| Submitted for opposition 30 on 27th Apr 2022 | Filed |